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Knock-in mice were generated that harbored a leucine-to-serine
mutation in the a4 nicotinic receptor near the gate in the channel
pore. Mice with intact expression of this hypersensitive receptor
display dominant neonatal lethality. These mice have a severe
deficit of dopaminergic neurons in the substantia nigra, possibly
because the hypersensitive receptors are continuously activated by
normal extracellular choline concentrations. A strain that retains
the neo selection cassette in an intron has reduced expression of
the hypersensitive receptor and is viable and fertile. The viable
mice display increased anxiety, poor motor learning, excessive
ambulation that is eliminated by very low levels of nicotine, and a
reduction of nigrostriatal dopaminergic function upon aging.
These knock-in mice provide useful insights into the pathophysi-
ology of sustained nicotinic receptor activation and may provide a
model for Parkinson’s disease.
The mechanism leading from nicotine intake to addiction isnot known in detail, but it begins with the activation of
neuronal nicotinic acetylcholine receptors (nAChRs). Nico-
tine elicits dopamine release in several regions of the brain,
presumably leading to the reward, motor, and addictive effects
(1, 2). The highest-affinity and most abundant nicotine binding
in the brain corresponds to the a4b2 nAChR (3). The a4
subunit is the principal partner for the b2 subunit in brain;
b2-containing receptors play an important role in nicotine
self-administration, in nicotine-stimulated electrophysiologi-
cal responses in midbrain neurons, and in nicotine-stimulated
dopamine release in the ventral striatum (4, 5). The a4 subunit
and tyrosine hydroxylase are colocalized in dopaminergic
neurons (6). Epidemiological studies show that smokers have
a lower incidence of Parkinson’s disease (7, 8), suggesting a
protective effect of nicotine via modulation of the dopami-
nergic system.
Both a4 and b2 knockout mice show only subtle alterations in
their physiology or behavior until they reach old age (4, 9, 10).
We have used a complementary strategy to understand the roles
of a4-containing nAChRs. We reasoned that gain of function
mutations might generate more noticeable phenotypes, and that
these phenotypes would gain relevance from the fact that
nicotine and some candidate analgesics (11) are agonists. We
have generated lines of knock-in mice by introducing a point
mutation into the M2 transmembrane region of the a4 subunit
to produce a hypersensitive receptor.
Materials and Methods
Xenopus Oocyte Injections and Electrophysiology. The a4 and b2
subunits were subcloned into pAMV-PA (12). Capped mRNA
transcripts were prepared, and a4yb2 (2 ng, 1:1) or a4L99Syb2
(0.2–0.5 ng, 1:1) were microinjected into Xenopus oocytes (12).
Twenty-four to seventy-two hours later, two-electrode voltage
clamp recordings (12) were made in solutions containing zero
Ca21.
Knock-in Mouse Construction. A 129ySvJ a4 genomic clone con-
taining exon 5 and the L99S mutation was inserted into pKO
Scrambler V907 (Lexicon-Genetics, The Woodlands, TX). A
neomycin resistance cassette, with a phosphoglycerate kinase
promoter and polyadenylation signal and flanked by loxP sites,
was inserted 163 bp downstream from exon 5 for positive
selection. The diphtheria toxin A chain gene with the RNA
polymerase II promoter was inserted to provide negative selec-
tion for random insertion. Embryonic stem (ES) cells were
electroporated with the linearized construct and screened by
Southern blot; the wild-type (WT) gene contains a 9.7-kb,
BamHI–BamHI fragment, and the mutant gene contains a
7.7-kb, BamHI–EcoRI fragment (Fig. 1D). The loxP-f lanked
neomycin resistance cassette was deleted in some ES cells by
transfection with a cytomegalovirus-Cre plasmid; this deletion
leaves only the 34 bp of one loxP site in the intron. Two lines of
mice were generated by injection of mutated ES cells into
C57BLy6 blastocysts, one with the neo cassette still present (neo
intact) and another with the neo cassette deleted (neo deleted).
The presence of the mutation was confirmed by sequence
analysis of PCR-amplified gene segments.
Histology and Immunocytochemistry. Embryos were surgically re-
moved from pregnant females. Tails were removed for genotyp-
ing. Embryos were fixed by cardiac perfusion (0.1 M PBS and 4%
formaldehyde), postfixed for 2 h, dehydrated in 20% sucrose,
and cryosectioned (10 mm) in frontal orientation. Staining was
performed with antisera for tyrosine hydroxylase (TH) (1:500)
(Chemicon) and a4 nAChR (1:500) (Santa Cruz Biotechnology)
and fluorescent secondary antibodies (1:500, Alexa 594, Alexa
488; Molecular Probes), respectively. For cell counts, sections
were stained with TH-antisera (Pel-Freez; 1:250) for indirect
immunohistochemistry according to the Vectastain ABC Elite
kit protocol (Vector Laboratories). Diaminobenzidine was used
as the chromogen, with nickel enhancement.
Midbrain Progenitor Cells. Midbrain progenitor cells were har-
vested, expanded, and differentiated as described (13), but
epidermal growth factor (20 ngyml) and basic fibroblast growth
Abbreviations: nAChRs, nicotinic acetylcholine receptors; ES, embryonic stem; WT, wild
type; TH, tyrosine hydroxylase; ED, embryonic day.
†J.S. and P.D. contributed equally to this work.
**To whom reprint requests should be addressed. E-mail: lester@caltech.edu.
The publication costs of this article were defrayed in part by page charge payment. This
article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C.
§1734 solely to indicate this fact.
2786–2791 u PNAS u February 27, 2001 u vol. 98 u no. 5 www.pnas.orgycgiydoiy10.1073ypnas.041582598
factor (ngyml) were used as mitogens in media treated with
choline oxidase. Cells were studied in whole-cell patch clamp
experiments (14).
Locomotion and Other Behaviors. Ambulation (Fig. 3 A, B, D, and
E) was measured in Pasadena. Single events represented dis-
ruption of two distinct light beams 10 cm apart in the cage (San
Diego Instruments). Nicotine (0.02 mgykg nicotine equivalent of
nicotine hydrogen tartrate salt dissolved in 0.9% saline) or
amphetamine (5 mgykg d-amphetamine sulfate dissolved in
0.9% saline) was injected i.p. in a volume of 100–200 ml (100
mly20 g body weight).
Mice were shipped to Boulder and acclimated for 21 days
before testing by personnel blind to the genotype at 110–133
days of age (22 each WT mice and mutant littermates). Week
1 involved baseline anxiety, measured in the elevated plus
maze (15, 16), followed by mirrored chamber (16, 17) and
lightydark box (16, 18). Week 2 involved startle and prepulse
inhibition of startle, then 3 days on the accelerating rotarod
(Ugo Basile, Varese, Italy), at speeds increasing gradually
from 4 to 40 rpm over 500 s. In week 3, contextual and cued
fear conditioning was as described (19), except that a 0.7-mA
shock was used for fear conditioning. A separate group of mice
derived from the first backcross onto C57BLy6J mice also were
tested for gross ataxia on a circular mesh (0.5 3 0.5 cm
squares) elevated 23 cm from a plastic square arena. All
behavioral data were analyzed with ANOVA procedures and
SPSS Version 9 software.
Results
Physiological Design and Recombinant Generation of Mutant Geno-
types. Extending previous studies with the neuronal homomeric
a7 and muscle nAChRs (20–22), we found that the Leu-99Ser
Fig. 1. Physiological design, recombinant construction, and genomic characterization of the a4 knockin mouse strains. Agonist concentration-response
relations of WT and mutated (a4L99S) rat a4b2 receptors expressed in oocytes (five oocytes for each curve). (A) Acetylcholine. (B) Nicotine. (C) Choline. The choline
responses of the WT receptor were not studied systematically, because there is no response at choline concentrations up to 1 mM, and higher concentrations
of choline block the channel. (Insert) Time course of the response to 30 mM choline, showing partial desensitization. (D) Targeting construct containing exon
5 with the Leu99Ser mutation, the neomycin resistance gene (neo) flanked by loxP sites, the diphtheria toxin A chain gene (DT), and the pKO V907 vector (pKO).
(E) Deletion of the neo cassette by transfecting the neo-intact ES cells with a cytomegalovirus-Cre plasmid generates neo-deleted ES cell lines. (F) Southern blot
analysis of genomic DNA from five embryonic stem-cell clones following digestion with BamHI and EcoRI restriction endonucleases and hybridization with a
flanking genomic fragment as a probe, indicated in E. Lines analyzed in lanes 1, 2, 4, and 5 contain DNA from two WT genes. Lane 3 shows a line with one WT
gene (9.7 kb, BamHI–BamHI as indicated in E) and one mutant gene (7.7 kb, BamHI–EcoRI in E). (G) Sequence analysis of DNA extracted from WT, heterozygous
(het), and homozygous (hom) neo-intact mice. The WT sequence at nucleotide position 142, corresponding to the codon at position 99 in the M2 region, is CTT,
encoding leucine; the mutant sequence is TCT, encoding serine.
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mutation in the a4 subunit (VTLCISVLLSLTVFLLLIT) shifts
the dose–response relation for acetylcholine and nicotine about
30-fold to the left for the a4b2 receptor tested in oocytes (Fig.
1 A and B). The mutated receptor also is activated to 20% of
maximal values by choline at a concentration (’10 mM) that is
detected in plasma and cerebrospinal f luid (Fig. 1C) (23). We
also noted increased 8-(diethylamino)octyl 3,4,5-trimethoxyben-
zoate hydrochloride (500 nM, nine oocytes) blockable leakage
currents in some oocytes expressing the a4L99Syb2 receptor
(24), and this may arise from constitutive activation of 1–2% of
the receptors; that is, channels open even in the absence of
agonist (25).
Fig. 1D shows the targeting construct employed in these
experiments; Fig. 1E shows the altered region of one a4 allele in
129ySvJ ES cells after homologous recombination and also after
Cre recombinase-mediated deletion of the neo selection cas-
sette. Fig. 1F shows a Southern blot indicating presence of the
recombinant neo-intact mutant a4 gene in an ES cell line.
Similar blots were used then to indicate Cre recombinase-
mediated deletion of the neo selection cassette. Chimeric males
from the resulting two mouse lines, neo-intact and neo-deleted,
were bred to C57BLy6 females to generate animals heterozygous
for the mutation, and mice were tested for the mutation by
sequencing of genomic DNA (Fig. 1G). Heterozygous animals
from the neo-deleted line do not feed and die within 24 hours
after birth; a breeding colony bearing this dominant neonatal
fatal gene could not be established.
Heterozygous mice from the neo-intact line are viable and
fertile, and a breeding colony has been established. (In this
paper, further use of ‘‘heterozygous’’ refers to this neo-intact
line.) Homozygous mutant animals from the neo-intact line do
not feed and die within the first postnatal day. The effect of the
Leu-99Ser mutation is probably reduced in heterozygous neo-
intact mice because (i) the extent of hypersensitivity, quantified
by the reduction in EC50, is expected to increase with the
proportion of mutated to normal a4 subunits in the pentameric
a4b2 complex (21, 22); and (ii) in Western blots not shown, we
find that 3-month-old heterozygous mice express somewhat
lower levels of a4 receptors than do WT littermates, in agree-
ment with previous studies on knock-in animals showing that the
neo cassette often results in reduced production of the mutated
protein (26).
Deficits of Dopaminergic Neurons. Embryos from matings of het-
erozygous neo-intact mice (WT, heterozygous, and homozygous
for the mutation) and embryos from matings of neo-deleted
chimeras with C57BLy6 females (WT and containing one copy
of the mutated gene) were collected at embryonic day (ED) 14,
16, and 18. Double immunolabeling with anti-TH and anti-a4
antibodies revealed numerous TH- and a4-immunoreactive cells
in the substantia nigra and the ventral tegmental area of WT and
heterozygous animals at age ED 14–18 (Fig. 2A). Brains from
mutant homozygous embryos of the neo-intact line and from
embryos of the dominant lethal neo-deleted line showed normal
numbers of immunoreactive cells at ED 14, but a marked
reduction in the number of these cells at ED 16 and 18 (Fig. 2
B and C). The severe deficit of nigral dopaminergic cells was the
most remarkable anatomical change we observed in the brain of
the knock-in mouse.
Because (a4Leu-99Ser)b2 mutant receptors expressed in Xe-
nopus oocytes are activated by choline at concentrations that
occur in plasma and cerebrospinal f luid (Fig. 1C), it is possible
that the deficit of dopaminergic neurons in mutant mouse
embryos is caused by constant activation of hypersensitive
nAChRs on these neurons. To test whether dopaminergic neu-
rons in heterozygous mutant mice are activated by choline, we
isolated midbrain neuronal progenitor cells at ED 14–16, dif-
ferentiated them, and observed responses to applied choline
(100 mM). There were choline-induced inward currents in neu-
ron-like cells derived from heterozygous mice, but much smaller
currents in those derived from WT animals (Fig. 2 D and E),
ruling out a major contribution from endogenous a7 nicotinic
receptors (27). In cells from homozygous neo-intact mice, the
responses to choline were so large that recordings were lost after
the first application.
Characterization of Heterozygote Motor Activity. There were no
gross physical differences between heterozygotes and WT lit-
termates of both sexes from the neo-intact line. The genotypes
did not differ in weight, and all exhibited normal grooming
behavior and social interactions with cage mates. There was no
significant effect of genotype on any measure of fear condition-
ing. Nonetheless, detailed characterization revealed a specific
pattern of behavioral differences between the heterozygotes and
WT mice.
Fig. 2. Detection and probable pathophysiological basis of dopaminergic neuron deficits in mutant mice. (A) Substantia nigra of WT (Left) and homozygous
neo-intact ED 18 embryos, double stained for the a4 subunit (green) and for TH (red). (B) Tyrosine hydroxylase staining of substantia nigra of WT (Left) and
heterozygous neo-deleted (Right) ED 18 embryos. (C) Cell counts of TH-positive neurons in substantia nigra of ED 16 to ED 18 embryos from WT, neo-intact, and
neo-deleted mice. The heterozygote (het) cell counts do not differ significantly from WT, but both the homozygous (homo) neo-intact (P , 0.01, t test) and the
neo-deleted cell counts (P , 0.05, t test) differ significantly from WT. (D) Whole-cell voltage-clamp recording of responses to two consecutive puffs of choline
(100 mM, 20 ms) in neuron-like cells differentiated from ED 16 midbrain neuronal progenitor cells. Upper trace, cell from a WT embryo; lower trace, cell derived
from a heterozygous neo-intact ED 16 embryo. (E) Mean 6 SEM of responses in neuron-like cells derived from heterozygous animals (n 5 5 cells) but little or
no response in cells from WT animals (n 5 7 cells; significant difference, P , 0.05, t test).
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When mice are placed in the test cage, they explore the new
surroundings and show a transiently increased level of ambula-
tion for ’30 min (Fig. 3A). During this period, the knock-in mice
show a significantly higher level of ambulation than the WT
controls. The genotype X time interaction was characterized by
[F(1,17) 5 5.2; P , 0.001]. Whereas WT mice are not affected
by an administration of 0.02 mgykg of nicotine, this treatment
sharply reduces the level of activity of the knock-in mice [group
X time interaction 5 F(1,14) 5 1.89; P , 0.05] (Fig. 3B).
Concentrations of nicotine that affect behavior of unhabituated
WT mice are 10- to 100-fold higher.
In the accelerating rotarod test, the a4 heterozygotes also
exhibited abnormalities in a measure of motor learning (Fig. 3C).
Heterozygotes and WTs performed equally on the first day of
testing. Both genotypes showed some improvement across days
in their ability to remain on the accelerating rotarod [F(2,80) 5
30.2; P , 0.001], but heterozygotes performed more poorly
overall on later days [F(1,40) 5 6.91; P , 0.012]. Because there
is little a4 expression in the cerebellum and we detected no gross
ataxia in the a4 heterozygotes (all six heterozygous and all 10
WT mice remained on the mesh for the entire 5-min test period),
we suggest that cerebellar function is normal in the a4 heterozy-
gotes. Thus the impairment of motor coordination is most likely
another correlate of dysfunction of dopaminergic neurons (albeit
to a lesser extent than the fatal cell loss in either the homozygous
neo-intact animals or in neo-deleted animals carrying even a
single copy of the mutant gene). The hypersensitive a4 allele did
not produce an overall change in reactivity as measured by
acoustic startle response, prepulse inhibition, contextual learn-
ing, or auditory cued conditioning.
Locomotor responses to amphetamine were examined as a
behavioral measure of nigrostriatal function. Intraperitoneal
injection of 5 mgykg amphetamine stimulated locomotion in
young (’3-month-old) mice, and there was no significant dif-
ference between WT mice and their heterozygous littermates.
When the same group of animals was tested at 11 months of age,
there was reduced amphetamine-induced locomotion in het-
erozygous but not in WT mice (Fig. 3 D and E). We suggest that
the reduction of the amphetamine response in older heterozy-
gous mice is due to accelerated loss of function in their dopa-
minergic neurons.
Increased Anxiety of Heterozygous Knockin Mice. Fig. 4 shows that
heterozygotes were significantly more anxious than WT mice. In
Fig. 3. Spontaneous and drug-modulated locomotion of WT and heterozygous (het) neo-intact mutants. (A) No treatment. Heterozygotes showed significantly
higher locomotion than WT mice at the beginning of the experiment (P , 0.001). (B) Nicotine, 0.02 mgykg, was injected 30 min after the start of behavioral
monitoring. The plot shows data averaged over the time periods, 10 min before (BL, baseline) and 5–15 min after injection. Heterozygous mice showed a
significant reduction of locomotor activity after nicotine injection (P , 0.05). There was no significant difference in noninjected animals (right-hand bars),
nicotine-injected control animals, or saline-injected WT or heterozygous animals (data not shown). (C) Heterozygotes were impaired compared with WTs on the
accelerating rotarod (P , 0.012) when tested for three sequential days (n 5 20–22 of each genotype). (D and E) The effect of amphetamine on locomotion of
WT and heterozygous (het) mice at two ages. Before drug administration, animals were allowed to habituate for 30 min. Ten male WT and 10 male heterozygous
mice showing at least a 3-fold increased activity over baseline in response to amphetamine at 3 months of age were selected for longitudinal follow-up studies.
(D) Comparison in amphetamine responses for heterozygotes at 3 months vs. 11 months of age. (E) The average activity is plotted for the period between 5 and
45 min after injection. The response at 11 months declines significantly compared with the response at 3 months in heterozygous mice [F(1,9) 5 12.72, P , 0.01]
but not in WT mice.
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the elevated plus maze (Fig. 4A), heterozygotes displayed more
anxiety as measured by percentage of entrances into open arm
[F(1,44) 5 7.35; P , 0.01], percentage of time in open arms
[F(1,44) 5 10.8; P , 0.002], percentage of time in the closed
arms [F(1,44) 5 6.64; P , 0.02], and the number of times to the
end of the open arm [F(1,44) 5 8.6; P , 0.005]. There was no
effect of genotype on percentage of time in the center [F(1,44) 5
1.82; not significant) or number of total entries into all arms
[F(1,44) 5 1.29; not significant].
There was no overall difference in activity in this maze, as
evidenced by a lack of difference in the total entries in all arms
and time spent in the center of the maze. These measures are
consistent with overall greater anxiety in the heterozygotes.
In another measure of anxiety, the mirrored chamber test (Fig.
4B), heterozygotes displayed more anxiety as measured by:
latency (seconds) to enter mirrored chamber [F(1, 44) 5 5.9; P ,
0.019] and number of entrances into the mirrored chamber
[F(1,44) 5 5.9; P , 0.014]. There was no difference in times
walking through the mirrored passage [F(1,44) 5 2.2; not
significant].
In a third test of anxiety, the lightydark box, heterozygotes did
not differ from WTs on the following measures: total transitions
(15.1 6 1.7 vs. 17.3 6 0.9); percentage of time in the light box
(34.6 6 2.8 vs. 31.0 6 1.3); latency to enter the dark side (17.6 6
2.7 vs. 12.6 6 1.9). This lack of difference in the lightydark box
compared with increased anxiety measured in other mazes has
been observed previously in a corticotropin-releasing hormone
receptor-2 null mutant mouse (28). Anxiety is a multidimen-
sional behavior, and each test may evaluate only a subset of these
dimensions.
Discussion
We report generation of mice expressing a hypersensitive a4
receptor by mutating a single amino acid in the M2 region. This
hypersensitivity results in a severe phenotype: perinatal death of
animals that carry either a single copy of the dominant neo-
deleted allele or two copies of the neo-intact mutant allele. The
phenotype of the a4 nAChR knock-in mice is more severe than
that of a4 or b2, or even of b2yb4 subunit null mutants (4, 9, 29),
arguing against the possibility that the lethality arises primarily
from enhanced desensitization or inactivation of a4-containing
receptors or from autonomic dysfunction. The phenotype is also
more severe than that of knock-in mice bearing a hypersensitive
mutation of the a7 nicotinic receptor at the 99 position (30); the
latter mice display recessive lethality of the neo-deleted line as
well as cell death in somatosensory cortex.
The brain of mutant embryos showed no gross abnormalities.
We chose to specifically investigate substantia nigra dopaminer-
gic neurons, both because these cells express high densities of
a4-containing receptors (6) and because NURR1 knock-out
mice, which specifically lack these neurons, also die shortly after
birth (31). Some mutant nAChRs that cause human slow-
channel congenital myasthenic syndrome are activated by serum
levels of choline, and this continuous channel activity is thought
to contribute to the pathophysiology of the disease (32). We
present evidence that continuous activation by choline is a likely
mechanism underlying the deficit of dopaminergic neurons.
Previous data also establish that chronic stimulation of nicotinic
receptors in the brain produces developmental anomalies, in-
cluding extensive cytotoxicity and premature withdrawal from
the cell cycle (33). Detailed studies of other brain regions that
express a4 receptors have yet to be completed. Knock-in animals
with gain of function mutations in nicotinic receptors may
become useful models for neurodegenerative diseases.
Our results with the viable neo-intact heterozygous a4
knock-in mice support a role for a4-containing receptors in the
control of baseline anxiety. Nicotine is known to reduce anxiety
or to produce a bimodal effect on anxiety (34). Nicotinic
receptors modulate the release of neurotransmitters that have
critical roles in the regulation of anxiety (g-aminobutyric acid,
dopamine, and serotonin) (35), and it will be important to
investigate the hypothesis that these mice have reduced g-ami-
nobutyric acid release. Functional changes due to the hypersen-
sitive nicotinic receptors on dopaminergic neurons in the a4
heterozygotes could also contribute at least in part to increased
anxiety. (Increased anxiety is often associated with Parkinson’s
disease.) Consistent with this possibility, treatment with D2 but
not D1 dopamine receptor antagonists increases anxiety in
rodents (36). Finally, locomotion of the heterozygous knock-in
mice is extremely sensitive to nicotine, suggesting that these mice
may also become a model for effects of nicotine on mammalian
brain and behavior.
Fig. 4. Increased anxiety in a4 heterozygotes (het) compared with WT mice
and in the elevated plus maze (A) and mirrored chamber (B) (n 5 22 mice of
each genotype) (1, 2). (A) Heterozygotes were significantly more anxious, as
measured by percentage of entrances into the open arms (P , 0.01), percent-
age of time in the open arms (P , 0.002), percentage of time in the closed arms
(P , 0.02), and entrances to the end of the open arms (P , 0.005). (B)
Heterozygotes were significantly more anxious in the mirrored chamber, as
measured by latency to enter the mirrored chamber (P , 0.026), percentage
of time in the mirrored chamber (P , 0.03), entrances into the mirrored
chamber (P , 0.02), but not by the number of entries into the mirrored
passage.
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